Newsroom

Download PDF Study designed to build upon safety profile demonstrated in TIVO-1 study CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Jun. 4, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS (TivozAnib Use veRsUs Sutent in advanced renal cell carcinoma (RCC): Patient Preference), to establish additional data regarding the investigational drug tivozanib when used as

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 30, 2012– AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Monday, June 4, 2012 at 7:30 a.m. (CT) to review the Phase 3 TIVO-1 data that will be presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO). The call can be accessed by dialing 1-800-215-2410

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 29, 2012– AVEO Oncology (Nasdaq: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 3:00 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay

Download PDF AV-203 is the Third AVEO Molecule to Enter Clinic CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 23, 2012– AVEO Oncology (Nasdaq: AVEO) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors. AV-203 is a monoclonal antibody that selectively targets the receptor ERBB3,

Download PDF – Tivozanib is the First Agent to Demonstrate Greater than One Year PFS in Patients without Prior Systemic Treatment – – First Pivotal Trial vs. Active Targeted Agent in First-Line Advanced RCC – – Study Results Demonstrate Unique Combination of Superior PFS and Favorable Tolerability – CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–May. 16, 2012– AVEO Oncology (NASDAQ:AVEO) and Astellas

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 3, 2012– AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the first quarter of 2012 and reviewed key first quarter accomplishments. “Since the achievement of the primary endpoint in our TIVO-1 study early in the first quarter, we’ve seen an increase in excitement in the medical oncology community for tivozanib

Download PDF Ficlatuzumab/Gefitinib Combination Was Well-Tolerated and Demonstrated Clinical Activity; Study Results Did Not Reach Statistical Significance Encouraging Signals of Anti-tumor Activity in Distinct Subpopulations CAMBRIDGE, Mass.–(BUSINESS WIRE)–May. 2, 2012– AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) announced today preliminary data from the exploratory, randomized Phase 2 study comparing the combination of ficlatuzumab and gefitinib, an EGFR tyrosine kinase

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 30, 2012– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences. Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Deutsche Bank 37th Annual Health Care Conference on Tuesday, May 8, 2012 at 3:30 p.m. (ET) at the InterContinental Hotel in Boston. David Johnston, chief financial officer, is scheduled